170 related articles for article (PubMed ID: 37641099)
1. Assessment of satisfaction with antiretroviral drugs and the need for long-acting injectable medicines among people living with HIV in Japan and its associated factors: a prospective multicenter cross-sectional observational study.
Ishihara M; Hikasa S; Tsukiji M; Kunimoto Y; Nobori K; Kimura T; Onishi K; Yamamoto Y; Haruta K; Kashiwabara Y; Fujii K; Shimabukuro S; Watanabe D; Tsurumi H; Suzuki A
AIDS Res Ther; 2023 Aug; 20(1):62. PubMed ID: 37641099
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
3. Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment.
Kremer IEH; Beaudart C; Simons J; Plieger H; Schroeder M; Hiligsmann M
AIDS Care; 2024 Apr; 36(4):536-545. PubMed ID: 37526109
[No Abstract] [Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Murray M; Pulido F; Mills A; Ramgopal M; LeBlanc R; Jaeger H; Canon V; Dorey D; Griffith S; Mrus J; Spreen W; Margolis D
HIV Res Clin Pract; 2019; 20(4-5):111-122. PubMed ID: 31533539
[No Abstract] [Full Text] [Related]
6. Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and/or housing instability.
Fletcher L; Burrowes SAB; Khan GK; Sabin L; Johnson S; Kimmel SD; Ruiz-Mercado G; Pierre C; Drainoni ML
Harm Reduct J; 2023 Jan; 20(1):4. PubMed ID: 36627679
[TBL] [Abstract][Full Text] [Related]
7. Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.
Ariyo OE; Jones CE
J Clin Virol; 2022 Jan; 146():105032. PubMed ID: 34883407
[TBL] [Abstract][Full Text] [Related]
8. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
[TBL] [Abstract][Full Text] [Related]
9. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
10. Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island.
Collins AB; Macon EC; Langdon K; Joseph R; Thomas A; Dogon C; Beckwith CG
J Urban Health; 2023 Oct; 100(5):1062-1073. PubMed ID: 37563518
[TBL] [Abstract][Full Text] [Related]
11. Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV.
Matza LS; Paulus TM; Garris CP; Van de Velde N; Chounta V; Deger KA
Patient; 2020 Aug; 13(4):409-422. PubMed ID: 32356146
[TBL] [Abstract][Full Text] [Related]
12. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
Benning L; Mantsios A; Kerrigan D; Coleman JS; Golub E; Blackstock O; Konkle-Parker D; Philbin M; Sheth A; Adimora AA; Cohen MH; Seidman D; Milam J; Kassaye SG; Taylor T; Murray M
BMC Womens Health; 2020 Jul; 20(1):152. PubMed ID: 32711509
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with patient satisfaction with antiretroviral therapy in Japan: A cross-sectional, multicenter study.
Hikasa S; Ishihara M; Tsukiji M; Kunimoto Y; Nobori K; Kimura T; Onishi K; Yamamoto Y; Haruta K; Kasiwabara Y; Fujii K; Kimura T
J Infect Chemother; 2024 Aug; 30(8):746-751. PubMed ID: 38365064
[TBL] [Abstract][Full Text] [Related]
15. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
Mantsios A; Murray M; Karver TS; Davis W; Galai N; Kumar P; Swindells S; Bredeek UF; García RR; Antela A; Gomis SC; Bernáldez MP; Czarnogorski M; Hudson K; Walters N; Kerrigan D
BMC Health Serv Res; 2021 Mar; 21(1):255. PubMed ID: 33743684
[TBL] [Abstract][Full Text] [Related]
16. Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options.
Dubé K; Campbell DM; Perry KE; Kanazawa JT; Saberi P; Sauceda JA; Poteat T; Evans D
AIDS Res Hum Retroviruses; 2020 Dec; 36(12):1054-1058. PubMed ID: 32829645
[TBL] [Abstract][Full Text] [Related]
17. Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol.
Langdon KJ; Hitch AE; Collins AB; Beckwith CG; Becker S; Tashima K; Rich JD
Addict Sci Clin Pract; 2023 Oct; 18(1):60. PubMed ID: 37838707
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adherence rates for antiretroviral, blood pressure, or mental health medications for HIV-positive patients at an academic medical center outpatient pharmacy.
Langness J; Cook PF; Gill J; Boggs R; Netsanet N
J Manag Care Spec Pharm; 2014 Aug; 20(8):809-14. PubMed ID: 25062074
[TBL] [Abstract][Full Text] [Related]
19. Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study.
Massaroni V; Delle Donne V; Borghetti A; Ciccullo A; Lombardi F; Giuliano G; Farinacci D; Visconti E; Tamburrini E; Di Giambenedetto S
AIDS Patient Care STDS; 2022 May; 36(5):178-185. PubMed ID: 35507326
[TBL] [Abstract][Full Text] [Related]
20. Implementing long-acting injectable antiretroviral treatments in Senegal: issues, challenges and conditions for introducing them. Qualitative study with healthcare providers and patients.
Carillon S; Laborde-Balen G; Diop M; Diop K; Breton G; Ndiaye B; Taverne B
AIDS Care; 2024 May; 36(5):703-709. PubMed ID: 37708454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
